Active, not recruitingPhase 1NCT06132945
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
Studying Hereditary clear cell renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Ritesh Kotecha, MD, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Cabozantinib(drug)
- Enrollment
- 2 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (7)
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Cancer Suffolk - Commack (All Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
- Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States
Collaborators
Exelixis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06132945 on ClinicalTrials.govOther trials for Hereditary clear cell renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07293351A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07401875A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)M.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT07489534Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal DysfunctionDaihong Liu
- ENROLLING BY INVITATIONNANCT06945640Evaluation of 'RUS NE' in Robot-Assisted Partial Nephrectomy: Efficacy, Safety, and StabilityHutom Corp
- RECRUITINGPHASE2NCT07229040A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patients Undergoing Debulking Surgery With Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.Hospital General Universitario Gregorio Marañon
- RECRUITINGNANCT07367750Testing the Feasibility of a Self-Management Support Program for Patient With Chronic Diseases in IsraelUniversity of Haifa
- RECRUITINGNCT07303725Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional OncologyPalo Alto Veterans Institute for Research
- RECRUITINGPHASE1NCT06623630Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal FunctionWashington University School of Medicine
See all trials for Hereditary clear cell renal cell carcinoma →